Department of Cardiology, Heart Centre, University Hospital, Umeå, Sweden.
Ups J Med Sci. 2011 Mar;116(1):52-9. doi: 10.3109/03009734.2010.517875. Epub 2010 Nov 16.
The main indication for ablation of supraventricular tachycardia is symptomatic relief. Generic measures of quality of life are not suitable for direct evaluation of arrhythmia-related symptoms, and a specific tool is needed. The questionnaire U22 quantifies symptoms associated with arrhythmic events. It uses discrete 0-10 scales for quantification of influence of arrhythmia on well-being, intensity of discomfort, type of dominant symptom, and a time aspect that summarizes duration and frequency of spells. We evaluated U22 in a well defined group of patients with paroxysmal supraventricular tachycardia, undergoing an intervention with a distinct end-point and a high success rate.
Symptoms in patients with accessory pathway and atrioventricular nodal re-entrant tachycardia scheduled for ablation were measured with U22 and SF-36 on admission. The evaluation was repeated after 6 months.
Altogether 58 patients successfully ablated in 2006-2008 completed the four forms (U22 and SF-36 at base-line and follow-up, 210 ± 35 days after ablation). The score for well-being (0-10; 10 being best) increased from 5.9 ± 2.6 to 7.9 ± 1.9 (P < 0.0005). The score for arrhythmia as cause for impairment in well-being (0-10; 10 being highest) decreased from 7.5 ± 2.8 to 2.0 ± 3.1 (P < 0.0005). The time aspect score (0-10) decreased from 4.7 ± 1.5 to 1.4 ± 1.8 (P < 0.0005). The two SF-36 summary measures PCS and MCS increased from 46.9 ± 9.4 to 48.4 ± 10.7 and from 44.9 ± 12.5 to 49.1 ± 9.9 (P = 0.04 and 0.002).
After successful ablation of accessory pathway and atrioventricular nodal re-entrant tachycardia, the U22 protocol detected a relevant increase in arrhythmia-related well-being. Modest improvement in general well-being was detected by the SF-36 protocol.
消融术治疗室上性心动过速的主要适应证是缓解症状。一般的生活质量指标不适合直接评估心律失常相关症状，因此需要特定的工具。U22 问卷用于量化与心律失常相关的症状。它使用离散的 0-10 刻度来量化心律失常对幸福感的影响、不适强度、主要症状类型以及概述发作持续时间和频率的时间方面。我们在一组明确的阵发性室上性心动过速患者中评估了 U22，这些患者接受了一种具有明确终点和高成功率的介入治疗。
在 2006 年至 2008 年期间，计划接受消融术的旁路和房室结折返性心动过速患者使用 U22 和 SF-36 入院时进行症状评估。在 6 个月后进行重复评估。
总共 58 例患者在 2006 年至 2008 年期间成功消融，完成了四种表格（基线和随访时的 U22 和 SF-36，消融后 210 ± 35 天）。幸福感评分（0-10；10 为最佳）从 5.9 ± 2.6 增加到 7.9 ± 1.9（P < 0.0005）。因心律失常导致幸福感下降的评分（0-10；10 为最高）从 7.5 ± 2.8 降至 2.0 ± 3.1（P < 0.0005）。时间方面的评分（0-10）从 4.7 ± 1.5 降至 1.4 ± 1.8（P < 0.0005）。SF-36 两个综合测量指标 PCS 和 MCS 从 46.9 ± 9.4 增加到 48.4 ± 10.7 和从 44.9 ± 12.5 增加到 49.1 ± 9.9（P = 0.04 和 0.002）。
在成功消融旁路和房室结折返性心动过速后，U22 方案检测到与心律失常相关的幸福感显著增加。SF-36 方案检测到一般幸福感的适度改善。
